telmisartan / Generic mfg. - LARVOL DELTA

A way forward for generic development of telmisartan tablets: Integrating critical material attributes and bio-predictive dissolution for target product profile. (PubMed, Eur J Pharm Biopharm) - "A rank-based approach was applied to evaluate a robust framework for understanding the differences between these generic formulations. This approach not only supports comprehensive formulation development through CMA-CQA correlations, but also aligns with regulatory expectations for adopting multi-dissolution methods as in vitro testing in cases of formulation change requirements with a bio-equivalance waiver for post-approval formulation changes."

Journal

The angiotensin II receptor antagonist telmisartan promotes renal recovery after ischemia-reperfusion injury by reprogramming fatty acid metabolism. (PubMed, Am J Physiol Cell Physiol) - "These transcriptomic findings 72 h after IRI were significantly blunted or even abolished by telmisartan. This treatment effects did not show evidence of direct PPAR-γ pathway activation, This study suggests that the metabolic modulatory effects of certain angiotensin II receptor blockers may provide therapeutic benefit during the recovery phase of AKI, independent of direct PPAR-γ signaling."

Journal • Acute Kidney Injury • Cardiovascular • Fibrosis • Immunology • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Reperfusion Injury

Telmisartan and Nicorandil Attenuate Polymyxin B-Induced Renal Injury by Modulating NrF2/NQO1, FAS/FASL Signaling, and Mitigation of P53, Cyt-C, and Caspase-3. (PubMed, Immunopharmacol Immunotoxicol) - "The renoprotective effects of telmisartan and nicorandil were mediated through modulation of the Nrf2/NQO1 antioxidant pathway and FAS/FASL apoptotic signaling, along with downregulation of renal expression of p53, cytochrome c, and caspase-3. These observations clearly indicate the protective role of both agents against PMB-induced nephrotoxicity."

Journal • Anesthesia • Infectious Disease • Metabolic Disorders • Renal Disease • CASP3 • FASLG • NQO1 • TP53

Assessing Renoprotective Effects of Empagliflozin and Telmisartan Combination Therapy in Non-albuminuric Diabetic Nephropathy: A Retrospective Cohort Study. (PubMed, Cureus) - "Combination therapy was associated with slower longitudinal eGFR loss, while event-based outcomes were imprecise, supporting larger prospective validation in normoalbuminuric DKD."

Journal • Retrospective data • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

The impact of PI3K/AKT signaling pathway of telmisartan combined with amlodipine for patients with elementary hypertension (ChiCTR) - P=N/A | N=96 | Completed | Sponsor: Zhengzhou Seventh People's Hospital; Zhengzhou Seventh People's Hospital

New trial • Cardiovascular • Hypertension

Seasonally different toxicity drivers in a river system revealed by insights from POCIS, bioassays, and suspect screening. (PubMed, Water Res) - "To address the identification gap in effect-directed analysis, a quantitative potency-balance approach integrating bioanalytical equivalents (BEQbio) and chemically predicted equivalents (BEQchem) identified telmisartan as a major contributor to PPARγ activity. These findings demonstrate that hydrological regime shifts can drive mechanistic changes in mixture toxicity and highlight the value of potency-based EDA for linking biological effects to causative chemicals."

Journal • PPARG

Seasonal and spatial dynamics of organic micropollutants in a Mediterranean river: implications for environmental risk assessment. (PubMed, Environ Geochem Health) - "Among the 27 tested pharmaceuticals, ibuprofen (4.7 µg/L), caffeine (23.6 µg/L), telmisartan (833.5 ng/L), carbamazepine (658.5 ng/L), gemfibrozil (71.0 ng/L), mefenamic acid (64.7 ng/L), and diphenhydramine (65.9 ng/L) were the most frequently detected, with some reaching notably high concentrations in the µg/L range in surface water. Sediments revealed ubiquitous contamination by ibuprofen, telmisartan, climbazole, diphenhydramine, and azithromycin...The findings from this study contribute to the state of knowledge of pollution levels of emerging contaminants in a major Mediterranean river and permit to inform and guide future mitigation and management strategies. The environmental risk assessment applied in this study enabled the translation of measured concentrations into ecologically meaningful indicators allowing the identification of priority contaminants and high-risk locations."

Journal

Advancing Drug Repurposing for Rheumatoid Arthritis: Integrating Protein-Protein Interaction, Molecular Docking, and Dynamics Simulations for Targeted Therapeutic Approaches. (PubMed, Curr Issues Mol Biol) - " This multi-tiered computational workflow identified Rifampicin, Telmisartan, Danazol, and Pimozide as the most promising repurposing candidates. The key innovation of this study is this sequential funnel approach, which integrates large-scale network data with atomic-level simulation to prioritize high-confidence drug candidates for RA. In conclusion, this study highlights the potential of repurposing FDA-approved drugs to target key proteins involved in RA, offering a cost-effective and time-efficient strategy to discover new therapies."

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • AKT1 • IL1B • IL6 • STAT3 • TNFA

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients (clinicaltrials.gov) - P1/2 | N=36 | Not yet recruiting | Sponsor: Tanta University

New P1/2 trial • Breast Cancer • Cardiomyopathy • Cardiovascular • Oncology • Solid Tumor

First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study. (IASLC-WCLC 2022) - "These positive results support the combination of Atez+Bev as a potential treatment option for non-Sq NSCLC with TBM≥10. This is the first trial to evaluate the combination of Bev and TBM≥10mut/Mb excluding other alterations with very good results, even superior to other ICI+chemotherapy combinations."

Clinical • IO biomarker • Immune Modulation • Inflammation • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • MDM2 • ROS1 • STK11 • TMB

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial. (PubMed, JAMA Oncol) - P2 | "This multicenter, single-arm, open-label, phase 2 nonrandomized controlled trial (Atezolizumab Plus Bevacizumab in First-Line NSCLC Patients [TELMA]) included treatment-naive patients aged 18 years or older with confirmed stage IIIB-IV nonsquamous NSCLC with TMB of 10 or more mutations/megabase and no EGFR, ALK, STK11, MDM2, or ROS1 alterations. These findings suggest that atezolizumab with bevacizumab is a potential treatment for high-TMB nonsquamous NSCLC. ClinicalTrials.gov Identifier: NCT03836066."

IO biomarker • Journal • Cardiovascular • Dermatology • Fatigue • Hypertension • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Pruritus • Renal Disease • Solid Tumor • ALK • EGFR • ROS1 • STK11 • TMB

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - P2 | N=33 | Recruiting | Sponsor: Tyler J Curiel | Not yet recruiting ➔ Recruiting | Initiation date: Aug 2025 ➔ Jan 2026

Enrollment open • Platinum resistant • Trial initiation date • Oncology • Ovarian Cancer • Solid Tumor

CARDIOVASCULAR BENEFITS OF TELMISARTAN IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (ACC 2026) - "Abstract is embargoed at this time."

Cardiovascular • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Telmisartan Inhibits Non-Small Cell Lung Cancer by Inducing Ferroptosis through the NRF2/GPX4 Signaling Axis. (PubMed, Curr Med Chem) - "Telmisartan inhibited NSCLC by inducing ferroptosis via the NRF2/GPX4 axis, offering a new therapeutic strategy and potential clinical application for NSCLC treatment."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • GPX4

Effect of Ang II Receptor Inhibition on GSK-3β/CREB/BDNF Signalling in REM Sleep Deprivation-Induced Memory Impairment. (PubMed, Neurochem Res) - "Telmisartan-treated SD groups demonstrated significantly improved cognitive performance, increased BDNF and CREB expression, decreased GSK-3β levels, and balanced oxidative stress markers. In conclusion, telmisartan protected against cognitive and biochemical damage caused by chronic REM sleep deprivation, likely through modulation of GSK-3β/CREB/BDNF signaling and reduction of oxidative stress."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Sleep Disorder • ATM • ETV6

Anatomical, Molecular-Genetic, and Phytochemical Study of Species from the Genus Equisetum in Bulgaria. (PubMed, Plants (Basel)) - "Five species of the genus Equisetum distributed in Bulgaria were studied: four species from the subgenus Equisetum (Equisetum arvense, E. telmateia, E. sylvaticum, and E. palustre) and one from the subgenus Hippochaete (E...In the phospholipid fraction, the major classes were phosphatidylethanolamine, phosphatidylcholine, phosphatidylinositol, and phosphatidic acids. The chemical composition of the studied species and their high biologically active lipid constituents suggested that they were suitable for application in various directions."

Journal

Newly Synthesized Telmisartan-Amino Acid Conjugates Exhibit Enhanced Cytotoxic Effects in Malignant Melanoma Cells. (PubMed, Molecules) - "These three compounds were also tested on the vemurafenib-resistant (A375R) and normal (HaCaT and MRC-5) cell lines, and compound 8 showed better cytotoxicity (IC50 = 8.84 ± 1.24 µM) and selectivity (>3.50) when compared to telmisartan (IC50 = 29.23 ± 3.88, selectivity > 2.40). All three compounds induced cell cycle arrest and disrupted mitochondrial morphology and membrane potential. These findings highlight their potential as non-antihypertensive telmisartan derivatives for melanoma therapy."

Journal • Melanoma • Oncology • Solid Tumor • BRAF

Neuroprotective Activities of Nigella sativa Ethanolic Extract and Telmisartan Against Fipronil-Induced Neurotoxicity in Rats via Regulation of Apoptosis, Endosomal Micro-autophagy, and miRNA-137-5p. (PubMed, Microsc Microanal) - "Electron microscopic examination of the combination group revealed the restoration of nuclear and mitochondrial structures with less glial activation and multivesicular bodies. In conclusion, the combination of NSt and Tel are notable agents in mitigating hippocampal neuronal necrosis and astrogliosis and reduced Fip-induced neurotoxicity."

IO biomarker • Journal • Preclinical • Oncology • BCL2 • CASP3 • CAT • GFAP • IL1B • IL6 • mTOR • TNFA

Non-invasive co-delivery of Axitinib and telmisartan via LDH-based nanocarriers for synergistic VEGF/Ang-2 inhibition in ocular neovascular diseases. (PubMed, J Control Release) - "In a diabetic retinopathy model, Axi/Tel-D@LDH-HA-GVS nanocomposites restored retinal structure and markedly reduced the expression of VEGF, Ang-2, TNF-α, and IL-6. Collectively, this study provides a promising non-invasive and synergistic strategy for targeted treatment of ocular neovascular diseases."

Journal • Diabetic Retinopathy • Ocular Inflammation • Ophthalmology • Retinal Disorders • IL6 • TNFA

Discovery of Essential Genes as Possible Targets for Prostate Cancer Drug Development. (PubMed, Int J Genomics) - "Following that, we considered these possible genes as targets for drugs, performed docking analysis with 255 meta-drug agents, and identified the top 10 candidate drugs (adapalene, ergotamine, imatinib, dutasteride, vistusertib, risperidone, zafirlukast, irinotecan hydrochloride, drospirenone, and telmisartan). This study uniquely combines multidataset transcriptomic integration, HubG prioritization, and MD validation to propose novel biomarker-drug pairings for PCa. The findings offer promising leads for future experimental and clinical validation."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BIRC5 • CDCA5 • NUSAP1

Population Pharmacokinetics of Amlodipine and Telmisartan Following Oral Administration of a Single-Pill Fixed-Dose Combination in Healthy Korean Male Subjects. (PubMed, Clin Drug Investig) - "To our knowledge, this is the first population PK study to characterize the PKs of amlodipine and telmisartan co-administered as a single-pill FDC and to identify preliminary covariates that may influence their PK profiles."

Journal • PK/PD data • Cardiovascular • Hypertension

Telmisartan ameliorates reproductive dysfunction, oxidative stress, and mitochondrial damages induced by fipronil in male rats via regulation of Nrf2/HO-1/PGC-1α/MNF2/DRP1. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "On the contrary, TEL effectively restored the testicular function hormones, testicular and epididymal histoarchitecture, antioxidant indices, PGC-1α, and TFAM, with downregulation in MDA levels and DRP1 mRNA transcript. In conclusion, TEL protects the testicular mitochondria against damage from FIP toxicosis by modulating the Nrf2/HO-1/PGC-1α/MNF2/DRP1 expressions."

Journal • Preclinical • Oncology • IL1B • PCNA • TFAM • TNFA

Cardioprotection without risk? meta-analysis of prophylactic agents in low-risk cancer patients on anthracyclines (ASH 2025) - "We included randomized controlled trials (RCTs) of prophylactic ACE inhibitors, ARBs, beta-blockers, statins, dexrazoxane, or SGLT2 inhibitors in adults without pre-existing cardiovascular risk factors...Agents studied included beta-blockers (nebivolol, carvedilol, bisoprolol), ACE inhibitors (ramipril), ARBs (telmisartan), and spironolactone. Treatment duration ranged from 4 months to 1 year; anthracycline doses reached up to 689 mg/m² (epirubicin) or 536 mg/m² (doxorubicin)...The protective benefit was greater in contexts involving higher cumulative anthracycline doses and concurrent cardiotoxic therapies such as trastuzumab...However, high heterogeneity limits firm conclusions. Given the moderate effect size and heterogeneity, further large-scale, well-formulated trials are essential to identify optimal cardioprotective agents and precise patient selection criteria."

Retrospective data • Breast Cancer • Congestive Heart Failure • Heart Failure • Oncology • Solid Tumor

Decoding the Neuroprotective Intervention of Angiotensin Receptor Blockers: A Multimodal Approach Using In Silico Network Pharmacology, Molecular Modeling, and In Vivo Validation of Key Markers. (PubMed, ACS Chem Neurosci) - "Building on these findings, this study sought to compare the activity of azilsartan with other commonly used ARBs, including telmisartan, olmesartan, valsartan, eprosartan, irbesartan, and candesartan, using an integrative network pharmacology approach. To experimentally validate these predictions, in vivo studies were conducted in a scopolamine-induced memory-impaired model, which demonstrated significant restoration of the levels of AKT1 and PIK3CA. These findings clearly demonstrate the PI3K/AKT modulating effects of azilsartan, reinforcing its repurposing potential in dementia and related disorders, thereby expanding novel therapeutic opportunities within this drug class."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • AKT1 • PIK3CA • PIK3CB

Efficacy and Safety of HB-1 for Panic Disorder (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: Honeybrains Biotech LLC | Trial completion date: Feb 2026 ➔ Feb 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Psychiatry